Cargando…

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607

BACKGROUND: The c-Met receptor tyrosine kinase is aberrantly activated in many solid tumors. In a prior study we showed that prostate cancer PC-3 cells exhibit constitutively activated c-Met without exogenous hepatocyte growth factor (HGF); however whether this characteristic is due to an endogenous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Yao, Siemann, Dietmar W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418572/ https://www.ncbi.nlm.nih.gov/pubmed/22639908 http://dx.doi.org/10.1186/1471-2407-12-198

Ejemplares similares

Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
por: Onken, Julia, et al.
Publicado: (2016)

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
por: Kentsis, Alex, et al.
Publicado: (2012)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture
por: Bergström, J D, et al.
Publicado: (1999)

A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation
por: Anastasi, Sergio, et al.
Publicado: (1997)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Autocrine EGF and TGF‐α promote primary and acquired resistance to ALK/c‐Met kinase inhibitors in non‐small‐cell lung cancer
por: Wang, Yueqin, et al.
Publicado: (2022)

Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion
por: Hughes, Veronica S., et al.
Publicado: (2019)

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
por: Petti, Consalvo, et al.
Publicado: (2014)

ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors
por: Escorcia, Freddy E., et al.
Publicado: (2020)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
por: Demkova, Lucia, et al.
Publicado: (2018)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

Structure of the met protein and variation of met protein kinase activity among human tumour cell lines.
por: Tempest, P. R., et al.
Publicado: (1988)

Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors
por: Yeh, Iwei, et al.
Publicado: (2015)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023)

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
por: Yan, S. Betty, et al.
Publicado: (2017)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Receptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1
por: Tesfay, Lia, et al.
Publicado: (2016)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

Stable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK Cells
por: Chu, Chia, et al.
Publicado: (2016)

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
por: Welsh, James W, et al.
Publicado: (2009)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
por: Zhao, Yuanyuan, et al.
Publicado: (2015)

Origin and evolution of plexins, semaphorins, and Met receptor tyrosine kinases
por: Junqueira Alves, Chrystian, et al.
Publicado: (2019)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
por: Mekki, Meriem Sarah, et al.
Publicado: (2018)

Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
por: Lien, Vegard Torp, et al.
Publicado: (2019)

Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase
por: Behshad, Elham, et al.
Publicado: (2010)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
por: Wang, Ying, et al.
Publicado: (2016)

HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
por: Fan, Gaofeng, et al.
Publicado: (2016)

Met receptor is essential for MAVS-mediated antiviral innate immunity in epithelial cells independent of its kinase activity
por: Imamura, Ryu, et al.
Publicado: (2023)

Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor with In Vitro Anti-Tumor Effects
por: Ndolo, Karyn Muzinga, et al.
Publicado: (2019)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
por: Lien, Vegard Torp, et al.
Publicado: (2020)

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
por: Xiong, Wenyuan, et al.
Publicado: (2022)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for MET-Amplified Tumors With MET-D1228X or MET-Y1230X Mutations
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s2q5dlt4s284fohtm91lu40mgi